Long-term open-label evinacumab study in homozygous familial hypercholesterolemia

Phase 3, open-label, single-arm trial of evinacumab in homozygous familial hypercholesterolemia (HoFH), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Long-term safety and tolerability of evinacumab in patients with homozygous familial hypercholesterolemia and Long-term safety and tolerability of evinacumab in adolescent patients with homozygous familial hypercholesterolemia. Started Aug 2019; status: completed.